8-K: Protara Therapeutics Announces Positive Interim Phase 2 Results for TARA-002 in Bladder Cancer

Protara Therapeutics reports promising interim data from its Phase 2 ADVANCED-2 trial, showcasing durable responses with TARA-002 in patients with Non-Muscle Invasive Bladder Cancer (NMIBC).

Summary

• Protara Therapeutics announced updated results from its Phase 2 ADVANCED-2 trial assessing TARA-002 in high-risk NMIBC patients.
• The data, presented at the 2025 American Urological Association Annual Meeting, showed encouraging complete response (CR) rates in both BCG-Unresponsive and BCG-Nave cohorts.
• In the BCG-Unresponsive cohort (5 patients), the CR rate at any time was 100%, with rates of 100% at six months, 80% at nine months, and 67% at 12 months.
• The BCG-Nave cohort (21 patients) showed a CR rate at any time of 76%, with rates of 63% at six and nine months, and 43% at 12 months.
• The majority of adverse events were Grade 1 and transient, with no Grade 3 or greater treatment-related adverse events.
• The company expects to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025.

Sentiment

Score: 8

Explanation: The document presents positive clinical data, indicating potential for TARA-002 in treating NMIBC. The high complete response rates and favorable safety profile contribute to a positive outlook, although risks associated with clinical trials and regulatory approvals remain.

Positives

• High complete response rates were observed in both BCG-Unresponsive and BCG-Nave cohorts.
• The treatment demonstrated encouraging durability of response up to 12 months.
• TARA-002 has a favorable safety and tolerability profile.
• The treatment is easily integrated into clinical workflow without major hurdles for patients or staff.
• The company is on track to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025.

Negatives

• The sample size for the BCG-Unresponsive cohort is small (5 patients), which may limit the generalizability of the results.
• The complete response rates in the BCG-Nave cohort decreased over time, from 63% at six and nine months to 43% at 12 months.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include those associated with clinical trials, regulatory approvals, market conditions, and the company's ability to secure financing.
• The company's financial guidance may not be as expected.
• Failure to attract and retain management and key personnel could impact the company's progress.

Future Outlook

Protara expects to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025 and continues to advance the ADVANCED-2 trial.

Management Comments

• Tom Jayram, M.D., stated that TARA-002 has shown impressive efficacy, safety profile, and 12-month durability in its Phase 2 trial and can be easily integrated into workflow.
• Jesse Shefferman, CEO of Protara Therapeutics, expressed pleasure with the competitive 12-month CR rates observed in both the BCG-Unresponsive and BCG-Nave cohorts.

Industry Context

The announcement addresses the unmet need for effective and durable therapies for high-risk NMIBC, especially given the ongoing shortage of BCG. TARA-002 represents a potential alternative treatment option in this space.

Comparison to Industry Standards

• The company is aligning with the FDA's 2024 guidance for developing drugs and biologics for treatment of BCG-unresponsive NMIBC.
• TARA-002 is being compared to OK-432, a broad immunopotentiator marketed as Picibanil in Japan by Chugai Pharmaceutical Co., Ltd., with Protara demonstrating manufacturing comparability between the two.

Stakeholder Impact

• Positive results could lead to a new treatment option for patients with NMIBC, improving their quality of life.
• Successful development and commercialization of TARA-002 could benefit Protara's shareholders.
• The company's employees may benefit from the company's success.

Next Steps

• Protara will continue to enroll BCG-unresponsive participants in the ADVANCED-2 trial.
• The company will present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025.
• Protara will continue to follow participants for safety and durability of response.

Key Dates

Keywords

TARA-002, NMIBC, Bladder Cancer, Complete Response, BCG-Unresponsive, BCG-Nave, Clinical Trial, Protara Therapeutics, ADVANCED-2, Cell Therapy